Leslie Harrold to Time Factors
This is a "connection" page, showing publications Leslie Harrold has written about Time Factors.
Connection Strength
0.595
-
Harrold LR, Reed GW, John A, Barr CJ, Soe K, Magner R, Saunders KC, Ruderman EM, Haselkorn T, Greenberg JD, Gibofsky A, Harrington JT, Kremer JM. Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-to-Target Approach to Care of US Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2018 03; 70(3):379-387.
Score: 0.086
-
Harrold LR, Stolshek BS, Rebello S, Collier DH, Mutebi A, Wade SW, Malley W, Greenberg JD, Etzel CJ. Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry. Clin Rheumatol. 2017 Apr; 36(4):895-901.
Score: 0.081
-
Harrold LR, Reed GW, Karki C, Magner R, Shewade A, John A, Kremer JM, Greenberg JD. Risk of Infection Associated With Subsequent Biologic Agent Use After Rituximab: Results From a National Rheumatoid Arthritis Patient Registry. Arthritis Care Res (Hoboken). 2016 12; 68(12):1888-1893.
Score: 0.079
-
Harrold LR, Peterson D, Beard AJ, Gurwitz JH, Briesacher BA. Time trends in medication use and expenditures in older patients with rheumatoid arthritis. Am J Med. 2012 Sep; 125(9):937.e9-15.
Score: 0.058
-
Harrold LR, Andrade SE, Briesacher B, Raebel MA, Fouayzi H, Yood RA, Ockene IS. The dynamics of chronic gout treatment: medication gaps and return to therapy. Am J Med. 2010 Jan; 123(1):54-9.
Score: 0.049
-
Curtis JR, Palmer JL, Reed GW, Greenberg J, Pappas DA, Harrold LR, Kremer JM. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021 08; 73(8):1114-1124.
Score: 0.027
-
Solomon DH, Yu Z, Katz JN, Bitton A, Corrigan C, Fraenkel L, Harrold LR, Smolen JS, Losina E, Lu B. Adverse Events and Resource Use Before and After Treat-to-Target in Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled Trial. Arthritis Care Res (Hoboken). 2019 09; 71(9):1243-1248.
Score: 0.024
-
Ogdie A, Palmer JL, Greenberg J, Curtis JR, Harrold LR, Solomon DH, Kavanaugh A, Kremer JM, Mease PJ. Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor. J Rheumatol. 2019 05; 46(5):475-482.
Score: 0.023
-
Curtis JR, Chen L, Greenberg JD, Harrold L, Kilgore ML, Kremer JM, Solomon DH, Yun H. The clinical status and economic savings associated with remission among patients with rheumatoid arthritis: leveraging linked registry and claims data for synergistic insights. Pharmacoepidemiol Drug Saf. 2017 Mar; 26(3):310-319.
Score: 0.020
-
de Lautour H, Taylor WJ, Adebajo A, Alten R, Burgos-Vargas R, Chapman P, Cimmino MA, da Rocha Castelar Pinheiro G, Day R, Harrold LR, Helliwell P, Janssen M, Kerr G, Kavanaugh A, Khanna D, Khanna PP, Lin C, Louthrenoo W, McCarthy G, Vazquez-Mellado J, Mikuls TR, Neogi T, Ogdie A, Perez-Ruiz F, Schlesinger N, Ralph Schumacher H, Scir? CA, Singh JA, Sivera F, Slot O, Stamp LK, Tausche AK, Terkeltaub R, Uhlig T, van de Laar M, White D, Yamanaka H, Zeng X, Dalbeth N. Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises. Arthritis Care Res (Hoboken). 2016 05; 68(5):667-72.
Score: 0.019
-
Rathbun AM, Harrold LR, Reed GW. Temporal effect of depressive symptoms on the longitudinal evolution of rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken). 2015 May; 67(6):765-75.
Score: 0.018
-
Ayers DC, Li W, Harrold L, Allison J, Franklin PD. Preoperative pain and function profiles reflect consistent TKA patient selection among US surgeons. Clin Orthop Relat Res. 2015 Jan; 473(1):76-81.
Score: 0.017
-
Rathbun AM, Harrold LR, Reed GW. Temporal associations between the different domains of rheumatoid arthritis disease activity and the onset of patient-reported depressive symptoms. Clin Rheumatol. 2015 Apr; 34(4):653-63.
Score: 0.017
-
Rathbun AM, Harrold LR, Reed GW. A description of patient- and rheumatologist-reported depression symptoms in an American rheumatoid arthritis registry population. Clin Exp Rheumatol. 2014 Jul-Aug; 32(4):523-32.
Score: 0.017
-
Curtis JR, Shan Y, Harrold L, Zhang J, Greenberg JD, Reed GW. Patient perspectives on achieving treat-to-target goals: a critical examination of patient-reported outcomes. Arthritis Care Res (Hoboken). 2013 Oct; 65(10):1707-12.
Score: 0.016
-
Kanaan AO, Donovan JL, Duchin NP, Field TS, Tjia J, Cutrona SL, Gagne SJ, Garber L, Preusse P, Harrold LR, Gurwitz JH. Adverse drug events after hospital discharge in older adults: types, severity, and involvement of Beers Criteria Medications. J Am Geriatr Soc. 2013 Nov; 61(11):1894-9.
Score: 0.016
-
Toh S, Li L, Harrold LR, Bayliss EA, Curtis JR, Liu L, Chen L, Grijalva CG, Herrinton LJ. Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics? Pharmacoepidemiol Drug Saf. 2012 May; 21(5):524-34.
Score: 0.014
-
Furst DE, Pangan AL, Harrold LR, Chang H, Reed G, Kremer JM, Greenberg JD. Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registry. Arthritis Care Res (Hoboken). 2011 Jun; 63(6):856-64.
Score: 0.014